[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363650-105":59,"doc-detail-363650-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nanobody-conjugated-theranostic-prodrug-targeting-v3-integrin-enables-precision-cancer-therapy-with-real-time-imaging","Nanobody-Conjugated Theranostic Prodrug Targeting αvβ3 Integrin Enables Precision Cancer Therapy With Real-Time Imaging","","Theranostic prodrugs that combine diagnostic and therapeutic functions offer a strong path for precision oncology. This study presents the rational design, synthesis, and preclinical evaluation of a nanobody-based αvβ3 integrin-targeted theranostic prodrug (NBD). A glutathione-responsive disulfide linker enables selective doxorubicin release in the tumor microenvironment, together with an aza-BODIPY near-infrared fluorophore for activatable imaging. Compared with cRGD-coupled controls, NBD shows enhanced tumor selectivity, intracellular activation, and cytotoxic potency, including prolonged retention and reduced systemic toxicity in vivo. Real-time imaging further tracks activation and distribution, supporting image-guided therapy and reduced off-target effects. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanobody-conjugated-theranostic-prodrug-targeting-v3-integrin-enables-precision-cancer-therapy-with-real-time-imaging/363650/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanobody-conjugated-theranostic-prodrug-targeting-v3-integrin-enables-precision-cancer-therapy-with-real-time-imaging/363650.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study described in the abstract?","Question",{"text":112,"@type":113},"To design, synthesize, and evaluate a nanobody-based αvβ3 integrin-targeted theranostic prodrug that enables both imaging and therapy for precision cancer treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the NBD prodrug achieve selective drug release and imaging?",{"text":117,"@type":113},"It uses a glutathione-responsive disulfide linker to release doxorubicin within the tumor microenvironment and an aza-BODIPY near-infrared fluorophore for activatable, image-guided monitoring.",{"name":119,"@type":110,"acceptedAnswer":120},"How does NBD performance compare with the cRGD peptide-conjugated counterpart?",{"text":121,"@type":113},"NBD demonstrates superior tumor selectivity, stronger intracellular activation, and higher cytotoxic potency in αvβ3-overexpressing cancer cell lines, along with improved in vivo retention and tumor suppression with minimal systemic toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363650,1790389823,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Advanced Healthcare Materials   \n[www.advhealthmat.de](www.advhealthmat.de)  \n RESEARCH ARTICLE   \nNanobody-Conjugated Theranostic Prodrug Targeting αvβ3 Integrin Enables Precision Cancer Therapy With Real-Time Imaging  \nSanu Karan1  Hyunseung Lee1  Rema Naskar2  Mi Young Cho1  Hye Sun Park1  Eun Hee Han1  Soumyadip Hore3  Sun Hee Cho1  Truc Ngoc Kim Lam1, 4  Taewoong Son1, 4  Tae Jung Park1, 5  Inkyu Hwang2 Jonathan L. Sessler6   Kwan Soo Hong1, 4, 5   \n1 Center For Target-to-Therapeutics Research, Korea Basic Science Institute, Cheongju, Republic of Korea  2 Immunology and Immunopharmacology Laboratory, College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea  3 Department of Chemistry, Korea Advance Institute of Science and Technology, Daejeon, Republic of Korea  4 Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon, Republic of Korea  5 Department of Chemistry, Chung-Ang University, Seoul, Republic of Korea  6 Department of Chemistry, The University of Texas at Austin, Austin, Texas, USA  \nCorrespondence: Jonathan L. Sessler ([sessler@cm.utexas.edu](sessler@cm.utexas.edu))  Kwan Soo Hong (kshong@kbsi.re.kr)  \nReceived: 22 October 2025  Revised: 3 April 2026  Accepted: 8 April 2026  \nKeywords: αvβ3 integrin | nanobody | near-infrared imaging | precision oncology | theranostic prodrug  \nABSTRACT  \nTheranostic prodrugs that integrate diagnostic and therapeutic functionalities represent a promising avenue for precision oncology. In this study, we report the rational design, synthesis, and preclinical evaluation of a nanobody-based αvβ3 integrin-targeted theranostic prodrug (NBD) . The system incorporates a glutathione-responsive disulfide linker to enable selective release of doxorubicin within the tumor microenvironment, alongside an aza-BODIPY near-infrared fluorophore that providesactivatable imaging capability. Compared to its cRGD peptide-conjugated counterpart (cRBD), NBD demonstrated superior tumor selectivity, intracellular activation, and cytotoxic potency in αvβ3-overexpressing cancer cell lines. In vivo studies using SKOV3 xenograft models confirmed prolonged tumor retention, enhanced drug accumulation, and potent tumor suppression, with minimal systemic toxicity. Moreover, real-time imaging enabled precise monitoring of prodrug activation and distribution. These findings highlight the unique advantages of nanobody-guided theranostic platforms in enabling targeted drug delivery, reducing offtarget effects, and facilitating image-guided therapy. The modular design of NBD provides a versatile framework for advancing personalized cancer treatment strategies.  \n1  Introduction  \nPrecision medicine and theranostics are approaches to healthcare that offer the promise of tailoring treatments and diagnostics to individual patient characteristics, thereby improving outcomes, reducing side effects, and increasing diagnostic accuracy [1, 2] . Precision medicine involves customizing therapies that exploit  \ndisease-specific information based on genetic, molecular, and environmental factors. It is exemplified by targeted treatments, such as imatinib for chronic myeloid leukemia, which specifically inhibits the BCR-ABL fusion protein [3, 4] . In favorable cases, the precision medicine approach accelerates drug development through the identification of biomarkers, reduces clinical trial failures by targeting appropriate patient groups, and lowers  \n\n| Sanu Karan, Hyunseung Lee, and Rema Naskar contributed equally to this work.\u003Cbr>|\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.\u003Cbr>© 2026 The Author(s) . Advanced Healthcare Materials published by Wiley-VCH GmbH. |\n\nAdvanced Healthcare Materials, 2026; 15:e05197 1 of 16  \n[https://doi.org/10.1002/adhm.202505","cbCaipZYTfqisIoh","https://ap.wps.com/l/cbCaipZYTfqisIoh","pdf",3517216,16,"English","# Introduction\n## Nanobodies in targeted therapy\n## Theranostics and real-time monitoring","[{\"question\":\"What is the main goal of the study described in the abstract?\",\"answer\":\"To design, synthesize, and evaluate a nanobody-based αvβ3 integrin-targeted theranostic prodrug that enables both imaging and therapy for precision cancer treatment.\"},{\"question\":\"How does the NBD prodrug achieve selective drug release and imaging?\",\"answer\":\"It uses a glutathione-responsive disulfide linker to release doxorubicin within the tumor microenvironment and an aza-BODIPY near-infrared fluorophore for activatable, image-guided monitoring.\"},{\"question\":\"How does NBD performance compare with the cRGD peptide-conjugated counterpart?\",\"answer\":\"NBD demonstrates superior tumor selectivity, stronger intracellular activation, and higher cytotoxic potency in αvβ3-overexpressing cancer cell lines, along with improved in vivo retention and tumor suppression with minimal systemic toxicity.\"}]","Nanobody-Conjugated Theranostic Prodrug Targeting αvβ3 Integrin Enables Precision Cancer Therapy With Real-Time Imaging | PDF",1790152427,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95756bf64356e2e66828bde9962a3ef3.webp",983,1283,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bf50800dc1e3c637efb97ab0b0f1e96.webp",982,1281,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e7c6cb5cbed562933da8e7760ae2ecc.webp",981,1280,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddeac60bced9c7e47c5465acf4d09fe3.webp",980,1279]